What are the side effects of Niraparib?

In the pooled safety profile of patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who received niraparib monotherapy and another clinical trial, the most common adverse reactions in 10% of patients were nausea, thrombocytopenia, anemia, fatigue, constipation, musculoskeletal pain, abdominal pain, vomiting, and neutropenia. After niraparib was put on the market, adverse events such as pancytopenia, hypersensitivity reactions (including anaphylaxis), posterior reversible encephalopathy syndrome (PRES), confusion/disorientation, hallucinations, cognitive impairment (such as memory impairment, attention disorder), non-infectious pneumonia, and hypertensive crisis have occurred.

Across all niraparib-naive patientsIn the PRIMA trial, 32% of niraparib-treated patients experienced serious adverse reactions, including thrombocytopenia, anemia, and small bowel obstruction. Fatal adverse reactions occurred in 0.4% of patients and included intestinal perforation and pleural effusion. Twelve percent of patients treated with niraparib permanently discontinued treatment due to adverse reactions, including thrombocytopenia, anemia, nausea, and neutropenia. Adverse reactions resulted in dose reduction or interruption in 80% of patients, the most common being thrombocytopenia, anemia, and neutropenia.

NiraparibThe original drug has been launched in China and is included in medical insurance, but reimbursement is limited to eligible patients. The price of a common specification100mg*30 capsules per box may be more than 5,000 yuan. The original niraparib drug marketed overseas is more expensive than domestically. There are also generic niraparib drugs produced in other countries. Their pharmaceutical ingredients are basically the same as those of the original niraparib drug sold domestically and abroad. The price of 100mg*30 tablets per box produced by a Bangladesh pharmaceutical factory may be more than 1,000 yuan (the price may fluctuate due to exchange rates).